Literature DB >> 9490088

Quality control of end results in a Danish adjuvant breast cancer multi-center study.

P S Hansen1, E Andersen, K W Andersen, H T Mouridsen.   

Abstract

In a Danish multi-center study, quality control was performed on off-study data for high-risk breast cancer patients included in protocols of adjuvant therapy. In the two protocols 4455 patients were randomized and 2477 were registered off-study. Data from these patients were validated by reviewing the patients' records. Incorrect data were observed in 16.2% of the cases who went off-study due to recurrence, other malignant disease or death. In 258 of 2133 patients unidentical locations were demonstrated. Of these, 104 showed a time difference also. A major difference in site of recurrence was found in 107 patients (5.0%), 43 of whom were upstaged from local to a distant recurrence and 64 were downstaged. A time difference of more than 30 days was found in 192 patients (9.0%) and in 17 the difference exceeded 366 days. A time difference only was found in 88 patients (4%). The major parameter in the statistical analysis of the two protocols, i.e. recurrence-free survival, was not significantly influenced by the validation.

Entities:  

Mesh:

Year:  1997        PMID: 9490088     DOI: 10.3109/02841869709001342

Source DB:  PubMed          Journal:  Acta Oncol        ISSN: 0284-186X            Impact factor:   4.089


  8 in total

1.  Statin prescriptions and breast cancer recurrence risk: a Danish nationwide prospective cohort study.

Authors:  Thomas P Ahern; Lars Pedersen; Maja Tarp; Deirdre P Cronin-Fenton; Jens Peter Garne; Rebecca A Silliman; Henrik Toft Sørensen; Timothy L Lash
Journal:  J Natl Cancer Inst       Date:  2011-08-02       Impact factor: 13.506

2.  Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and risk of breast cancer recurrence: a Danish nationwide prospective cohort study.

Authors:  Gitte Vrelits Sørensen; Patricia A Ganz; Steven W Cole; Lars A Pedersen; Henrik Toft Sørensen; Deirdre P Cronin-Fenton; Jens Peter Garne; Peer M Christiansen; Timothy L Lash; Thomas P Ahern
Journal:  J Clin Oncol       Date:  2013-05-06       Impact factor: 44.544

3.  Stanniocalcin Expression as a Predictor of Late Breast Cancer Recurrence.

Authors:  Kristen D Brantley; Anders Kjærsgaard; Deirdre Cronin-Fenton; Rami Yacoub; Anja S Nielsen; Kristina L Lauridsen; Stephen Hamilton-Dutoit; Timothy L Lash
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-03-28       Impact factor: 4.254

Review 4.  Statins and breast cancer prognosis: evidence and opportunities.

Authors:  Thomas P Ahern; Timothy L Lash; Per Damkier; Peer M Christiansen; Deirdre P Cronin-Fenton
Journal:  Lancet Oncol       Date:  2014-09       Impact factor: 41.316

5.  Glucocorticoid prescriptions and breast cancer recurrence: a Danish nationwide prospective cohort study.

Authors:  L W Lietzen; T Ahern; P Christiansen; A B Jensen; H T Sørensen; T L Lash; D P Cronin-Fenton
Journal:  Ann Oncol       Date:  2014-09-15       Impact factor: 32.976

6.  Increased cardiovascular risk factors in breast cancer survivors identified by routine measurements of body composition, resting heart rate and arterial blood pressure.

Authors:  David H Jones; Melisa Nestore; Sara Henophy; Julia Cousin; Alain Steve Comtois
Journal:  Springerplus       Date:  2014-03-19

7.  Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.

Authors:  T L Lash; L Pedersen; D Cronin-Fenton; T P Ahern; C L Rosenberg; K L Lunetta; R A Silliman; S Hamilton-Dutoit; J P Garne; M Ewertz; H T Sørensen
Journal:  Br J Cancer       Date:  2008-07-29       Impact factor: 7.640

8.  Manganese superoxide dismutase and breast cancer recurrence: a Danish clinical registry-based case-control study, and a meta-analysis.

Authors:  Deirdre P Cronin-Fenton; Mariann Christensen; Timothy L Lash; Thomas P Ahern; Lars Pedersen; Jens Peter Garne; Marianne Ewertz; Herman Autrup; Henrik T Sørensen; Stephen Hamilton-Dutoit
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.